Century Therapeutics, Inc.
Century Therapeutics, Inc. (Nasdaq: IPSC) is a biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells for type 1 diabetes, autoimmune diseases and cancer. Its platform combines cell differentiation, CRISPR gene editing, proprietary Allo-Evasion technology… From the company’s description.
In fiscal 2025, Century Therapeutics, Inc. reported revenue of $109.16M, up 1556.8% from fiscal 2024, and a net loss of $9.58M. Its operating margin was −15.8%, and operations used $103.88M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Century Therapeutics, Inc. does
In the company’s own words
Century Therapeutics, Inc. (Nasdaq: IPSC) is a biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells for type 1 diabetes, autoimmune diseases and cancer. Its platform combines cell differentiation, CRISPR gene editing, proprietary Allo-Evasion technology and scalable manufacturing to produce beta islet cells, T cells and natural killer cells. The company’s pipeline includes CNTY-813, a beta islet replacement candidate for type 1 diabetes; CNTY-308, a CD19-targeted CAR-T candidate for B-cell-mediated diseases; and CNTY-101, a CD19-targeted CAR-NK candidate being studied in an investigator-sponsored trial for autoimmune diseases. It also develops next-generation T-cell programs for B-cell malignancies and solid tumors. Century operates as a biotechnology research and development company, with no reportable operating segments described here. Its 53,000-square-foot manufacturing facility in New Jersey produces clinical supplies and is intended to support multiple cell types. Its website is https://centurytx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1850119
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Century Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Century Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Century Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Century Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Century Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”